0000899243-23-003525.txt : 20230202
0000899243-23-003525.hdr.sgml : 20230202
20230202174108
ACCESSION NUMBER: 0000899243-23-003525
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230131
FILED AS OF DATE: 20230202
DATE AS OF CHANGE: 20230202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Richard Robert E.
CENTRAL INDEX KEY: 0001816151
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39273
FILM NUMBER: 23582518
MAIL ADDRESS:
STREET 1: C10 LYRA THERAPEUTICS, INC.
STREET 2: 1480 ALSENAL WAY
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001327273
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 ARSENAL WAY
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-373-4600
MAIL ADDRESS:
STREET 1: 480 ARSENAL WAY
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: 480 Biomedical, Inc.
DATE OF NAME CHANGE: 20120927
FORMER COMPANY:
FORMER CONFORMED NAME: Arsenal Vascular, Inc.
DATE OF NAME CHANGE: 20110826
FORMER COMPANY:
FORMER CONFORMED NAME: Arsenal Medical, Inc.
DATE OF NAME CHANGE: 20090414
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-31
0
0001327273
Lyra Therapeutics, Inc.
LYRA
0001816151
Richard Robert E.
C/O LYRA THERAPEUTICS, INC.
480 ARSENAL WAY
WATERTOWN
MA
02472
0
1
0
0
SVP, Technical Operations
Common Stock
2023-01-31
4
A
0
30000
0.00
A
30000
D
Stock Option
2.85
2023-01-31
4
A
0
45000
0.00
A
2033-01-30
Common Stock
45000
45000
D
Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in four (4) equal annual installments on the first four anniversaries of the grant date such that the RSUs will fully vest on January 31, 2027.
This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2023.
/s/ Jason Cavalier, Attorney-in-Fact for Robert E. Richard, Ph.D.
2023-02-02